Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction.
Pediatr Hematol Oncol
; 35(7-8): 427-433, 2018.
Article
em En
| MEDLINE
| ID: mdl-30596314
ABSTRACT
OBJECTIVE:
Since patients with langerhans cell histiocytosis and neurologic dysfunction (LCH-ND) often have incomplete treatment responses we sought a new treatment regimen. Because of clinical benefit from rituximab in multiple sclerosis patients with neurodegeneration, we evaluated its use in patients with LCH-ND.PARTICIPANTS:
Eight LCH-ND patients who had failed prior therapies.METHODS:
Charts of the 8 patients treated with rituximab were reviewed. Signs/symptoms and MRI responses were assessed.RESULTS:
Seven of eight patients experienced some clinical improvement gait abnormalities and tremors in four children, proprioceptive deficits in 2, and dysarthria/dysphagia in 2. Five of eight patients demonstrated improvement in intellectual/behavioral/psychological symptoms.CONCLUSION:
These findings suggest that prospective studies are warranted to define safety and efficacy of rituximab for patients with LCH-ND.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Histiocitose de Células de Langerhans
/
Rituximab
/
Doenças do Sistema Nervoso
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article